Carol Cronenberger

691 citations

28 papers · 540 indexed · h-index 13

Immunology
Pediatrics, Perinatology and Child Health top 10%
Physiology
Pharmacology top 10%
Rheumatology

Co-authors: Kevin Sweeney Ana Ruiz-Garcı́a Jing Dong Michael K. Smith Steve Riley P Chan Haiqing Dai Wonkyung Byon
Topics: Biosimilars and Bioanalytical Methods (16 papers)Pharmaceutical studies and practices (13 papers)Alzheimer's disease research and treatments (7 papers)
Cited by: Immunology Pediatrics, Perinatology and Child Health Biological Psychiatry
Journals: Annals of the Rheumatic Diseases British Journal of Clinical Pharmacology Drug Metabolism and Disposition
Partner nations: United States United Kingdom Germany

In The Last Decade

Carol Cronenberger

28 papers receiving 526 citations

Peers

Countries citing papers authored by Carol Cronenberger

Since Specialization

Citations

This map shows the geographic impact of Carol Cronenberger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carol Cronenberger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carol Cronenberger more than expected).

Fields of papers citing papers by Carol Cronenberger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carol Cronenberger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carol Cronenberger. The network helps show where Carol Cronenberger may publish in the future.

Co-authorship network of co-authors of Carol Cronenberger

This figure shows the co-authorship network connecting the top 25 collaborators of Carol Cronenberger. A scholar is included among the top collaborators of Carol Cronenberger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carol Cronenberger. Carol Cronenberger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Proposing a framework to quantify the potential impact of pharmacokinetic drug–drug interactions caused by a new drug candidate by using real world data about the target patient population 2024 ·Clinical and Translational Science ·Simon Dagenais,Christine U. Lee,Carol Cronenberger,(unknown),Vaishali Sahasrabudhe	2
2	Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis: a phase 3, open-label, randomised, parallel-group study 2023 ·The Lancet Rheumatology ·Roy Fleischmann,(unknown),Sharad Lakhanpal,(unknown),Donna S. Cox,(unknown),Wuyan Zhang,Carol Cronenberger,Karen Wang	8
3	Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis 2022 ·Rheumatology and Therapy ·Roy Fleischmann,(unknown),Wuyan Zhang,(unknown),Ivana Vranić,Carol Cronenberger,Eva Dokoupilová	4
4	Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial 2021 ·Arthritis Research & Therapy ·Roy Fleischmann,(unknown),(unknown),Carol Cronenberger,Ivana Vranić,Wuyan Zhang,Rieke Alten	12
5	Randomized, Open‐Label, Single‐Dose, Parallel‐Group Pharmacokinetic Study of PF‐06410293 (adalimumab‐afzb), an Adalimumab Biosimilar, by Subcutaneous Dosing Using a Prefilled Syringe or a Prefilled Pen in Healthy Subjects 2021 ·Clinical Pharmacology in Drug Development ·Donna S. Cox,(unknown),(unknown),Carol Cronenberger	3
6	Interchangeability of Biosimilars: What Level of Clinical Evidence is Needed to Support the Interchangeability Designation in the United States? 2020 ·BioDrugs ·(unknown),Gertjan Wolbink,Carol Cronenberger,John Orazem,Jonathan Kay	28
7	Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54–78 Data From a Randomized, Double-Blind, Phase III Trial 2020 ·BioDrugs ·Stanley Cohen,S. Radominski,Hideto Kameda,Alan Kivitz,Michael Tee,Carol Cronenberger,Min Zhang,(unknown),(unknown),Oliver von Richter,Rieke Alten	12
8	AB0289 EFFICACY, SAFETY AND IMMUNOGENICITY IN PATIENTS WITH RHEUMATOID ARTHRITIS COMPARING PF-06410293 (ADL-PF), AN ADALIMUMAB (ADL) BIOSIMILAR, AND REFERENCE ADL: RESULTS FROM WEEK 26–52 OF A DOUBLE-BLIND, RANDOMISED PHASE 3 STUDY INCLUDING PATIENTS WHO SWITCHED FROM ADL-PF TO REFERENCE ADL AT WEEK 26 2020 ·Annals of the Rheumatic Diseases ·Roy Fleischmann,(unknown),(unknown),Carol Cronenberger,Ivana Vranić,(unknown),Rieke Alten	2
9	Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin®) in patients with advanced non-squamous non-small cell lung cancer 2019 ·Cancer Chemotherapy and Pharmacology ·(unknown),Kevin Sweeney,Carol Cronenberger	7
10	A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis 2018 ·Arthritis Research & Therapy ·Roy Fleischmann,Rieke Alten,Margarita Pileckytė,Kasia Lobello,Steven Y. Hua,Carol Cronenberger,Daniel Alvarez,(unknown),K. Lea Sewell	42
11	FRI0137 Efficacy, safety and immunogenicity from week 30 to week 54 in a randomised, double-blind phase iii study comparing a proposed infliximab biosimilar (PF-06438179/GP1111) with reference infliximab 2018 ·Annals of the Rheumatic Diseases ·Rieke Alten,Vira Tseluyko,Tomas Hala,(unknown),Margarita Pileckytė,Eva Dokoupilová,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Carol Cronenberger,(unknown),Oliver von Richter,Bogdan Batko	3
12	Extension Study of PF‐05280586, a Potential Rituximab Biosimilar, Versus Rituximab in Subjects With Active Rheumatoid Arthritis 2018 ·Arthritis Care & Research ·Stanley Cohen,Rubén Burgos‐Vargas,Paul Emery,Bo Jin,Carol Cronenberger,(unknown)	22
13	Ponezumab in mild‐to‐moderate Alzheimer's disease: Randomized phase II PET‐PIB study 2017 ·Alzheimer s & Dementia Translational Research & Clinical Interventions ·Jaren W. Landen,Niels Andreasen,Carol Cronenberger,Pamela F. Schwartz,Anne Börjesson‐Hanson,(unknown),(unknown),Brendon Binneman,Martin M. Bednar	49
14	Establishing Best Practices and Guidance in Population Modeling: An Experience With an Internal Population Pharmacokinetic Analysis Guidance 2013 ·CPT Pharmacometrics & Systems Pharmacology ·Wonkyung Byon,Michael K. Smith,P Chan,(unknown),Steve Riley,Haiqing Dai,Jing Dong,Ana Ruiz-Garcı́a,Kevin Sweeney,Carol Cronenberger	152
15	Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimerâs disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study 2013 ·International Journal of Clinical Pharmacology and Therapeutics ·Izuru Miyoshi,Yoko Fujimoto,(unknown),(unknown),Qinying Zhao,Carol Cronenberger,Kanae Togo,(unknown),Martin M. Bednar,James W. Kupiec,Brendon Binneman	20
16	P4‐209: Safety, tolerability, pharmacokinetics and pharmacodynamics of monthly and quarterly doses of Ponezumab (PF‐04360365) in subjects with mild‐to‐moderate Alzheimer's disease 2012 ·Alzheimer s & Dementia ·Jaren W. Landen,Niels Andreasen,Carol Cronenberger,(unknown),Anne Börjesson‐Hanson,(unknown),(unknown),James W. Kupiec,Brendon Binneman,Martin M. Bednar	3
17	P1‐012: Effect of ponezumab on CSF biomarkers: Pooled analysis of phase IIa studies in subjects with mild‐to‐moderate Alzheimer's disease 2012 ·Alzheimer s & Dementia ·Carol Cronenberger,(unknown),Kathryn Wright,Kelly R. Bales,Kaj Blennow,Henrik Zetterberg,Jaren W. Landen,Scot Styren,(unknown),Brendon Binneman	18
18	How Current Understanding of Clearance Mechanisms and Pharmacodynamics of Therapeutic Proteins Can Be Applied for Evaluation of Their Drug-Drug Interaction Potential 2011 ·Drug Metabolism and Disposition ·Eugenia Kraynov,Steven W. Martin,Susan Hurst,Odette A. Fahmi,Martin E. Dowty,Carol Cronenberger,Cho‐Ming Loi,Bing Kuang,(unknown),Scott Fountain,Michel Awwad,Diane Wang	14
19	Population pharmacokinetic analysis of carboxyhaemoglobin concentrations in adult cigarette smokers 2007 ·British Journal of Clinical Pharmacology ·Carol Cronenberger,Diane R. Mould,(unknown),Mohamadi Sarkar	24
20	The Hepatic First‐Pass Metabolism of Problematic Drugs 1993 ·The Journal of Clinical Pharmacology ·David Lalka,(unknown),Carol Cronenberger	20

About Carol Cronenberger

Carol Cronenberger is a scholar working on Immunology, Pediatrics, Perinatology and Child Health and Statistics and Probability, having authored 28 papers that have together received 540 indexed citations. Recurring topics across this work include Biosimilars and Bioanalytical Methods (16 papers), Pharmaceutical studies and practices (13 papers) and Alzheimer's disease research and treatments (7 papers). The work is most often cited by research in Immunology (173 citations), Pediatrics, Perinatology and Child Health (135 citations) and Biological Psychiatry (17 citations). Carol Cronenberger has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Kevin Sweeney, Ana Ruiz-Garcı́a, Jing Dong, Michael K. Smith, Steve Riley, P Chan, Haiqing Dai, Wonkyung Byon, Brendon Binneman and Martin M. Bednar. Their work appears in journals such as Annals of the Rheumatic Diseases, British Journal of Clinical Pharmacology and Drug Metabolism and Disposition.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact